Tirbanibulin 1% ointment as a potential novel treatment for anogenital warts

S Braasch¹, P A Gerber^{2

3}, S A Braun^{1

3}

Affiliations

¹ Department of Dermatology, University Hospital Muenster, Muenster, Germany.
² Dermatologie am Luegplatz, Duesseldorf, Germany.
³ Department of Dermatology, Medical Faculty, Heinrich-Heine University, Duesseldorf, Germany.

S Braasch et al. J Eur Acad Dermatol Venereol. 2022 Jun.

. 2022 Jun;36(6):e468-e470.

doi: 10.1111/jdv.17957. Epub 2022 Feb 3.

S Braasch¹, P A Gerber^{2

3}, S A Braun^{1

3}

¹ Department of Dermatology, University Hospital Muenster, Muenster, Germany.
² Dermatologie am Luegplatz, Duesseldorf, Germany.
³ Department of Dermatology, Medical Faculty, Heinrich-Heine University, Duesseldorf, Germany.

No abstract available

References

1. Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2020; 34: 1644-1653.
1. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36: 1397-1403.
1. Drolet M, Brisson M, Maunsell E et al. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis 2011; 38: 949-956.
1. Smolinski MP, Bu Y, Clements J et al. Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361). J Med Chem 2018; 61: 4704-4719.
1. European medicines Agency EMA. Klisyri. [WWW document]. URL https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri (last accessed 4 November 2021).